ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.

Preliminary Figures for the First Half of 2009

24.07.2009

Order intake for the Biotechnology Division surged 8.8% 
(currency-adjusted: +5.8%) to 203.5 million euros (previous year: 
187.1 mn euros) and sales revenue rose 7.4% (currency-adjusted: 
+4.3%) to 197.8 million euros from 184.1 mn euros a year ago. This 
gain was fueled by business with single-use products at clearly 
dou-ble-digit growth rates.

For the Mechatronics Division, order intake in the first six months 
fell cyclically from 124.1 million euros to 102.9 million euros 
(-17.1%; currency-adjusted:  20.3%). At the same time, sales revenue 
dropped from 119.9 million euros to 98.7 million euros (-17.7%; 
currency-adjusted: -20.9%).

On the whole, the Sartorius Group received orders valued at 306.4 
million euros (311.3 mn euros), which equates to a decline of 1.6% 
(currency-adjusted: -4.6%). Consolidated sales revenue eased 2.5% 
(currency-adjusted: -5.6%) and is at 296.5 million euros (304.0 mn 
euros).

Consolidated earnings before interest, taxes and amortization and 
adjusted for one-time extraordinary expenses (underlying EBITA) are 
at 24.7 million euros (27.0 mn euros), which corresponds to a margin 
of 8.3% (8.9%). The Biotechnology Division contributed to this growth
with 28.0 million euros (20.4 mn euros) and a margin increase from 
11.1% to 14.2%. At -3.4 million euros (6.6 mn euros), the 
Mechatronics Division delivered negative earnings. One-time 
extraordinary expenses essentially entail provisions for the 
restructuring program currently being implemented in the Mechatronics
Division, and total 16.3 million euros.

Without the two non-cash items of amortization and interest for share
price warrants, consolidated underlying net profit after minority 
interest is at 6.4 million euros (9.6 mn euros); the corresponding 
earnings per share are at 0.37 euro (0.56 euro). Actual consolidated 
net profit after minority interest amounts to -8.1 million euros (7.3
mn euros). As of June 30, 2009, net debt was reduced to 181.9 million
euros (Dec. 31, 2008: 217.6 mn euros).

For fiscal 2009, our forecast remains unchanged, with the 
Biotechnology Division´s revenue expected to grow and its earnings to
increase overproportionately. For the Mechatronics Division, we 
project a double-digit decline in revenue and a negative earnings 
contribution. Given the continued high uncertainty regarding the 
global economy, we still consider it not possible to make a precise 
full-year forecast.

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius,
will discuss the first-half figures with analysts and investors on 
Tuesday, July 28, 2009, at 3:15 p.m. Central European Time (CET), in 
a teleconference. You may dial into the teleconference starting at 
3:00 p.m. CET at the following numbers: Germany +49 (0)69 5007 1317; 
France +33 (0)1 70 99 43 01; UK +44 (0)20 7806 1966; USA +1 718 354 
1389 The dial-in code is: 7760640 The webcast and presentation can be
viewed at www.sartorius.com.

end of announcement                               euro adhoc

Further inquiry note:

Andreas Wiederhold
Team Leader Treasury & Investor Relations
Telefon: +49 (0)551 308-1668
E-Mail: andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade